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Abstract  Perfusion  MRI  is  an  essential  part  of  characterizing  salivary  gland  tumors.  The  shape
of the  curves  can  provide  a  guide  as  to  the  type  of  lesion:  benign  (ascending  plateau)  or  malig-
nant (descending  plateau),  and  can  also  occasionally  strongly  suggest  a  histological  type  such  as
a Warthin  tumor  (intense,  rapid  contrast  enhancement  with  washout  >  30%).  Perfusion  imaging
(CT or  MRI)  for  other  head  and  neck  tumors  is  currently  being  developed  and  is  being  assessed.
It should  be  a  tool  to  assist  in  choosing  the  most  appropriate  initial  treatment  (chemotherapy,
radiotherapy  or  surgery)  and  should  also  allow  poor  responders  to  conservative  treatment  to
be identiﬁed  and  recurrences  to  be  detected  in  post-treatment  damaged  tissues.  Aims:  (a)  to
determine  when  to  perform  perfusion  MRI;  (b)  to  determine  the  type  of  perfusion  to  carry  out:
CT, T1-weighted  MRI;  (c)  to  determine  how  to  position  the  region  of  interest  to  plot  the  per-
fusion curve;  (d)  to  know  how  to  interpret  MRI  curves  for  salivary  gland  tumors;  (e)  to  know
how to  interpret  the  information  obtained  from  perfusion  CT  or  MRI  for  the  upper  aerodigestive
tract.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Perfusion  imaging,  with  CT  or  MRI,  can  provide  non-invasive  access  to  the  microcirculatory
features  of  tissue  lesions.  The  two  methods  which  can  be  used  in  ENT  imaging  are  CT
perfusion  and  T1-weighted  perfusion  MRI.
Clinicians’  requirements  differ  depending  on  the  disease  and  the  related  problems  in
treating  them  which  are  raised.  Perfusion  methods  seek  to  answer  these  practical  patient
care  problems.  They  therefore  have  differing  merits,  depending  on  the  type  and  site  of
the  head  and  neck  tumor.The  question  faced  by  the  surgeon  for  a  salivary  gland  tumor  is  whether  to  operate
or  not.  The  answer  to  this  depends  on  the  type  and  site  of  the  lesion.  We  will  see  that
perfusion  MRI  provides  what  have  become  essential  answers  for  the  surgeon  from  the  initial
diagnostic  and  pre-treatment  assessment.
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The  questions  which  clinicians  currently  face  with  upper
erodigestive  tract  tumors  (UADT)  are  related  to  the  com-
lex  nature  of  the  treatments  which  are  available.  These
nclude  chemotherapy  and  radiotherapy,  and  possibly  both
conservative  treatment)  or  surgery.  Surgery  may  be  carried
ut  ﬁrst  line  or  as  a  salvage  procedure  after  conservative
reatment  has  failed.  ENT  surgery  is  often  mutilating  and
aises  two  problems,  one  functional  (voice  and  swallowing)
nd  the  other  aesthetic.  Organ  preservation  protocols  are
herefore  becoming  more  popular  and  are  becoming  increas-
ngly  complex,  in  order  to  avoid  initial  mutilating  surgery.
t  is  essential,  therefore,  to  be  able  to  distinguish  those
atients  who  will  beneﬁt  from  conservative  treatment  from
hose  who  need  surgery.  The  following  problems  arise:
can  we  predict  which  patients  will  beneﬁt  from  a con-
servative  radiochemotherapy  approach  from  the  initial
CT  or  MRI  investigation  before  any  treatment  is  offered?
Also,  it  is  possible  to  predict  which  patients  who,  on  the
other  hand,  will  not  respond  and  will  beneﬁt  from  surgery
from  the  beginning?  Salvage  surgery  is  extremely  difﬁcult,
particularly  after  radiotherapy,  and  carries  a  high  risk  of
complications  and  local  failure.  It  is  therefore  very  impor-
tant  to  identify,  wherever  possible  from  the  start,  which
patients  need  surgery  as,  although  it  is  mutilating,  ini-
tial  surgery  carries  less  risk  and  offers  a  greater  chance
of  local  control  of  the  disease  when  it  is  performed  ﬁrst
line;
is  it  possible  to  predict  the  response  to  conservative  treat-
ments  (radiotherapy,  chemotherapy  or  a  combination  of
both),  in  order  to  determine  the  optimal  treatment  on  an
individual  case  basis?  Do  we  have  information  to  suggest
that  a  patient  will  respond  well,  and  what  is  the  patient’s
likelihood  of  achieving  a  complete  response  after  conser-
vative  treatment?
can  we  objectively  quantify  and  monitor  the  response  to
conservative  treatments?
can  we  detect  poor  responders  to  conservative  treatment
early?  In  particular,  can  we  detect  poor  responders  to
radiotherapy  and  then  stop  the  radiotherapy,  to  direct
the  patient  to  surgery  more  quickly?
can  we  detect  recurrences  after  treatment  early,  and  dis-
tinguish  these  from  inﬂammatory  changes  or  radiation
necrosis?
can  we  obtain  information  which  would  allow  us  to  opti-
mally  assess  lymph  nodes  under  a  centimeter  in  size  so
that  the  lymph  nodes  are  only  removed  if  they  are  gen-
uinely  diseased?
We  shall  examine  the  following  issues  in  succession  in  this
rticle:
routine  perfusion  MRI  techniques  which  are  essential  for
characterizing  salivary  tumors,  in  order:  to  establish  when
to  perform  a  perfusion  sequence,  to  decide  what  type
of  perfusion  to  perform,  how  to  acquire  and  analyze  the
images,  how  to  position  the  regions  of  interest  and  how  to
plot  the  perfusion  curve  in  signiﬁcant  areas  and  be  able
to  interpret  the  MRI  curves  to  characterize  salivary  gland
tumors;
techniques  which  are  currently  being  developed  and
assessed  using  CT  and  MRI  for  UADT  carcinomas,  in  order:
to  establish  when  to  carry  out  a  perfusion  sequence,  to
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know  which  technique  to  use  and  to  be  able  to  interpret
functional  parameters  from  perfusion  imaging.
erfusion imaging for salivary gland tumors
eneral details
RI  has  become  an  essential  further  investigation  for  any
pace-occupying  lesion  in  a  salivary  gland.  Salivary  gland
umor  pathology  is  complicated  and  includes  a large  variety
f  lesions.
In  decreasing  order  of  frequency,  the  salivary  gland
umors  include:
benign  tumors  which,  do  however  need  to  be  excised  sur-
gically  because  of  the  risk  of  malignant  degeneration:  this
is  the  case  for  pleomorphic  adenomas;
benign  tumors  which  usually  do  not  need  any  surgery:
this  is  the  case  for  Warthin  tumors  which  are  not  treated
surgically  provided  that  formal  evidence  of  the  tumor  is
obtained  by  ﬁne  needle  aspiration  and  MRI.  They  are  then
only  treated  surgically  for  aesthetic  or  comfort  reasons;
low-,  intermediate-  or  high-grade  malignant  tumors
which  always  require  surgical  excision:  muco-epidermoid
squamous  cell  carcinomas,  cystic  adenoid  carcinomas,
adenocarcinomas,  squamous  cell  carcinomas,  and  undif-
ferentiated  carcinomas;
malignant  tumors  which  require  systemic  therapy:  lym-
phomas;
rare  benign  tumors  which  do  not  require  surgery:
branchial  cysts,  HIV  lympho-epithelial  cysts,  oncocy-
tomas,  hemolymphangiomas  and  lipomas.
The  ﬁrst  question  the  surgeon  needs  to  answer  is  there-
ore  whether  or  not  he/she  needs  to  operate.  One  of  the
erits  of  MRI  and  ﬁne  needle  aspiration  is  that  they  have
llowed  us  to  avoid  always  resorting  to  surgery  to  establish
he  type  of  lesion.  The  second  question  the  surgeon  faces
s  the  risk  of  malignancy.  In  parotid  tumors,  surgeons  also
ant  to  assess  the  risk  to  the  facial  nerve.  In  this  case,  the
ims  of  MRI  are  to  determine  the  exact  site  of  the  lesion  and
o  provide  information  in  order  to  characterize  it,  to  assist
he  surgeon  in  his/her  decision  of  whether  or  not  to  oper-
te  and  to  help  him  to  warn  patients  of  the  increased  risk
f  temporary  or  permanent  postoperative  facial  paralysis  if
alignant  disease  is  assumed  from  MRI  ﬁndings.
In  this  situation,  perfusion  MRI  provides  essential  infor-
ation  for  preoperative  characterization  of  salivary  gland
esions,  provided  that  it  is  performed  and  interpreted  rigor-
usly.
echnique and image processing
he  aim  of  MRI  investigation  of  a salivary  gland  lesion
s  to  determine  the  site,  size,  margins  and  T1-  and  T2-
eighted  signal  characteristics  of  the  lesion  (without  fat
aturation).  It  has  now  been  clearly  established  that  diffu-
ion  imaging  is  essential  and  provides  information  about  the
ellularity  of  the  lesion  and  its  malignant  potential  [1—3].
owever,  the  diagnostic  accuracy  of  diffusion-weighted  MRI
ither  alone  or  combined  with  conventional  T1-  and  T2-
eighted  sequences  is  inadequate  [4].  This  ‘‘conventional’’
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the  lesion.  These  T1  hyperintensities  are  due  to  a  pro-
tein  component  within  the  lesion  or  the  presence  of  blood,Perfusion  in  ENT  imaging  
approach  has  particular  failings  in  Warthin  tumors  and
cellular  pleomorphic  adenomas,  both  of  which  can  con-
tain  a  hypercellular  component  with  nodules  which  greatly
reduces  diffusion,  incorrectly  suggesting  a  malignant  tumor
which  requires  surgical  excision.  As  we  have  seen  above,
Warthin  tumors  do  not  require  surgery  as  they  carry  no  risk
whatsoever  of  malignant  degeneration.  With  cellular  pleo-
morphic  adenomas,  even  if  surgery  is  required,  the  risk  to
the  facial  nerve  and  the  prognosis  are  different  from  those
of  malignant  tumors.
Although  conventional  sequencing  and  diffusion  can  be
ineffective  for  Warthin  tumors  and  cellular  pleomorphic
adenomas,  it  has  now  been  clearly  established  that  they
have  highly  suggestive  and  speciﬁc  enhancement  features
on  T1-weighted  perfusion  [5,6].
A  full  investigation  of  a  salivary  gland  tumor  must,
therefore,  include  T1-weighted  perfusion  MRI  sequences  in
addition  to  the  conventional  T1-,  T2-weighted  and  diffusion-
weighted  sequences  [2,7,8].
We  shall  not  describe  the  T1  perfusion  technique  here
and  refer  the  reader  to  the  techniques  chapter.
We  would  like  simply  to  draw  readers’  attention  to  a few
speciﬁc  features  of  salivary  gland  imaging:
• it is  very  important  to  tell  the  patient  that  they  must  not
swallow;
• the  FOV  must  be  suitable  for  the  cervical  region:  a  small
FOV,  i.e.  28  cm;
• the  matrix  also  needs  to  be  increased:  192  ×  192;
• section  thickness  must  be  suitable  for  the  anatomical
region:  4  mm.
A  detailed  acquisition  protocol  is  proposed  in  Boxed  text
1.
In  image  processing,  it  is  important  to  understand  that
salivary  gland  tumors  are  heterogeneous  and  made  up  of
different  components  (greater  or  lesser  cell  density,  a  myx-
oid  component,  a  calciﬁed  component  and  a  more  or  less
hemorrhagic  ﬂuid  content).  T1-  and  T2-weighted  signals  and
diffusion  restriction  and  contrast  enhancement  vary  accord-
ing  to  the  type  of  these  different  components.  The  choice
of  the  region  of  interest  in  which  the  perfusion  curve  is  con-
structed  (and  similarly  measurement  of  the  apparent  rADC
diffusion  coefﬁcient)  is  therefore  fundamental:
• clearly  the  perfusion  curve  should  not  be  plotted  for  a
non-tissue  portion  which  does  not  enhance.  Hemorrhagic
areas  or  those  made  up  of  high  protein  content  ﬂuid  which
Boxed  text  1  Acquisition  parameters  for  MR
perfusion  sequence.
MR  perfusion  sequence
Injection:  0.2  mmol/kg  via  a  power  injector  at  a  rate
of  4  mL/s,  followed  by  injection  of  20  mL  of  normal
saline
SPGR  3D;  8  slices
Section  thickness:  4  mm
40 phases
Temporal  resolution:  3—4  s
Matrix:  192  ×  192
FOV:  28  cm
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are  hyperintense  on  an  unenhanced  T1  sequence  are  seen
very  commonly  in  Warthin  tumors  and  must  therefore  be
excluded  (Fig.  1).  It  is  also  essential  not  to  place  the
region  of  interest  in  necrotic  areas,  which  are  hyperin-
tense  on  T2  and  produce  variable  signals  on  T1  sequences.
These  are  common  in  malignant  tumors.  It  is  also  impor-
tant  to  be  aware  of  calciﬁed  acellular  areas  or  those  made
up  of  a myxoid  matrix,  which  are  very  common  in  pauci-
cellular  pleomorphic  adenomas;
therefore,  it  is  preferable  to  use  areas  which  are
hypointense  on  T2  and  not  hyperintense  on  T1  sequences
in  order  to  determine  the  position  of  the  region  of  interest
(Fig.  2).
Finally,  as  contrast  is  used,  we  suggest  that  the  inves-
igation  be  completed  by  T1-weighted  sequences  with  fat
aturation  after  contrast  injection.
nterpretation of MRI images
n  light  of  the  above,  MRI  characterization  of  a  salivary
land  tumor  should  incorporate  all  of  the  anatomical,  signal
nd  functional  information  (diffusion  and  perfusion)  which
t  provides  [9].
orphology  of  the  lesion
he  size  and  position  of  the  lesion  (superﬁcial  or  deep  part
f  the  gland),  relationships  with  the  stylomastoid  foramen
nd  the  retrocondylar  veins  (which  are  a  marker  for  the  path
f  the  facial  nerve),  well  or  poorly  demarcated  outlines  and
ny  potential  extension  to  the  subcutaneous  tissues  (par-
icularly  fat)  and  masseter  muscle  should  be  reported.  The
eport  should  state  the  presence  or  absence  of  a  contralat-
ral  lesion  (suggestive  of  Warthin’s  tumor  or  lymph  nodal
umors).  Lymphadenopathy  in  zone  II  should  also  be  investi-
ated.
ignal  from  the  lesion
1:  the  main  beneﬁt  of  this  sequence  is  that  it  allows
s  to  investigate  for  an  unenhanced  T1  hyperintensity  inoth  of  which  suggest  a  diagnosis  of  Warthin’s  tumor,
igure 1. Incorrect choice of the position of the region of inter-
st (ROI). a: axial T1-weighted MRI: unenhanced T1 hyperintensity
black arrow) representing bleeding within the lesion; b: uninfor-
ative, ﬂat perfusion curve.
1228  S.  Espinoza  et  al.
F : axial T1-weighted MRI; b: axial T2-weighted MRI. Green ROI positioned
i d sequences. c: informative enhancement curve.
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Figure 3. Hyperintense T2 signal. T2 axial MRI: right intraparotid
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aigure 2. Correct choice of the position of the region of interest. a
n the tissue portions which are hypointense on T1- and T2-weighte
ven  if  they  are  limited  to  within  the  lesion.  Also,  it  is
mportant  to  identify  these  areas  before  contrast  enhance-
ent  in  order  not  to  be  misled  by  increased  uptake  and
o  centre  the  perfusion  sequence  away  from  these  areas
Fig.  1).
T2  sequence  without  fat  saturation:  this  sequence  is
sed  to  study  the  signal  from  the  lesion  compared  to  the
ealthy  parotid  parenchyma.  A  strong  T2  hyperintensity
ompared  to  the  healthy  parotid  parenchyma  suggests  a
enign  tumor  (pleomorphic  adenoma,  Fig.  3).  An  interme-
iary  T2-weighted  signal  may  represent  either  a  cellular
leomorphic  adenoma  (Fig.  4a),  or  an  intermediary-grade
alignant  tumor  (Fig.  4b).  A  strong  T2  hypointensity  com-
ared  to  the  healthy  parenchyma  suggests  a  malignant
umor  (Fig.  5).
In  a  diffusion-weighted  sequence  with  rADC  measure-
ent,  the  signal  from  the  lesion  should  be  compared  to  the
ealthy  neighboring  or  contralateral  parotid  parenchyma
nd  the  result  expressed  as  an  apparent  diffusion  coefﬁcient
atio  (rADC)  compared  to  the  healthy  parenchyma  (tumor
DC/healthy  parotid  ADC).  A  strong  hyperintense  tumor  on
 diffusion-weighted  sequence  with  an  apparent  diffusion
oefﬁcient  ratio  of  under  1,  suggests  a  high-grade  malig-
ant  lesion  (Fig.  6a)  whereas  a  tumor  with  an  apparent
d
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igure 4. Intermediary T2-weighted signal. a: axial T2-weighted MRI
denoma; b: axial T2-weighted MRI: intermediary T2 signal from an inteumor with a pronounced T2-weighted hyperintensity which is
reater than the glandular parenchyma and suggestive of a pleo-
orphic adenoma.
iffusion  coefﬁcient  ratio  of  over  1.3  suggests  a  benign  pleo-
orphic  adenoma  (Fig.  6b).  An  ADC  ratio  of  between  1  and
.3  may  represent  either  a  cellular  pleomorphic  adenoma  or
n  intermediary-grade  malignant  tumor  (Fig.  6c).
: intermediary T2 signal from a right parotid cellular pleomorphic
rmediary-grade malignant left parotid tumor.
Perfusion  in  ENT  imaging  1229
Figure 5. Low T2 signal. Axial T2-weighted MRI: pronounced
hypointense T2 sequence compared to the normal glandular
parenchyma, suggestive of a high-grade malignancy tumor.
Figure 7. Necrotic area in the tumor. Axial T1-weighted MRI after
gadolinium with fat saturation, showing a large central portion
which does not enhance. This lesion is very difﬁcult to character-
ize in a perfusion sequence because of the extensive cystic changes
which make unequivocal positioning of the ROI difﬁcult in principle
(
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malignancy  detection  and  90  to  100%  for  a  Warthin  tumor)
[5];In  a  T1-weighted  sequence  after  gadolinium  injection  and
fat  saturation,  the  investigation  can  clearly  demarcate  the
lesion  and  also  distinguish  cystic  and  necrotic  components
which  do  not  enhance  (Fig.  7),  which  should  be  excluded
retrospectively  from  the  ROI  in  calculating  the  rADC  and
in  tracing  the  perfusion  curve  —  tissue  components  which
enhance  late  and  can  be  used  to  calculate  the  rADC  and  to
obtain  the  perfusion  curve.
Finally,  the  enhancement  curve  from  the  perfusion
sequence:  on  this  type  of  T1-weighted  perfusion  sequence,
a  pleomorphic  adenoma  (regardless  of  its  cellularity)
has  extensive  contrast  uptake  with  an  ascending  plateau
(Fig.  8a),  a  Warthin  tumor  has  intense  and  rapid  con-
trast  uptake  with  a  high  washout  of  over  30%  (Fig.  8b)
and  intermediary-grade  malignant  tumors  have  intense  con-
trast  uptake  with  a  horizontal  or  descending  plateau  but  a
washout  of  under  30%  (Fig.  8c).Figure 6. Diffusion mapping with rADC measurement in 3 different pa
the tumor and normal parotid (0.55) suggestive of a malignant tumor; 
tumor and normal parotid (1.4) suggestive of a benign pleomorphic ad
ratio between the tumor and normal parotid (0.9) which may represent
malignant tumor.before injection) in a part of the tissue.
he  place  and  limitations  of  perfusion  MRI
t  has  now  been  clearly  established  that  MRI  for  the
nvestigation  of  a  salivary  gland  tumor  should  include  a
1-weighted  perfusion  sequence  with  recording  of  the
nhancement  curve  and  that  these  should  be  interpreted
ointly,  taking  account  of  all  of  the  information  provided.
Perfusion  MRI  alone  is  insufﬁcient  for:
tumors  containing  a  largely  cystic  component  in  which
positioning  the  region  of  interest  is  difﬁcult  or  impossi-
ble  (Fig.  1).  rADC  measurement  has  the  same  limitations
in  this  situation;
the  speciﬁcity  of  the  three  types  of  curves  obtained  is
extremely  high,  but  is  not  pathognomonic  for  a  histolog-
ical  type  of  tumor  (it  has  a  speciﬁcity  of  80  to  91%  fortients. a: diffusion mapping showing a very low ADC ratio between
b: diffusion mapping showing a very high ADC ratio between the
enoma tumor; c: diffusion mapping showing an intermediary ADC
 either a cellular pleomorphic adenoma or an intermediary-grade
1230  S.  Espinoza  et  al.
Figure 8. The three possible perfusion curves: a: ascending plateau: curve suggestive of a benign pleomorphic adenoma tumor; b: peak
with washout more than 30% typical of a Warthin tumor; c: descending plateau with washout less than 30%: this curve is suggestive of a
m
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Falignant tumor.
tumors  under  10  mm  in  size  are  difﬁcult  to  characterize  on
perfusion  MRI,  although  they  are  also  difﬁcult  in  general
even  when  all  of  the  sequences  are  considered,  because
of  their  small  size  and  probably  also  because  they  do  not
yet  express  a  sufﬁcient  number  of  functional  components.
As  a  result,  a  salivary  gland  MRI  investigation  should  con-
ain  the  following  three  features:
a T2-weighted  sequence  without  fat  saturation;
a  diffusion-weighted  sequence  with  measurement  of  the
ADC  ratio;
I
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If  it  does  not,  the  investigation  does  not  provide  all  of  the
ssential  information  to  characterize  the  lesion,  and  reduces
ts  diagnostic  accuracy.nterpretation  algorithm
his  is  shown  in  Fig.  9.
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Diagnosis
The  diagnosis  should  be  made  consistent  with  the  features
of  the  lesions  which  are  shown  in  Table  1  and  in  Figs.  10—14.Summary
An  MRI  for  the  investigation  of  a  salivary  gland  tumor
should  contain  a  T1-weighted  perfusion  sequence.  However,
t
c
Table  1 Diagnostic  criteria.
T2  ADC  ratio
Whartin’s  tumor  Hypo  or  Iso  0.8—1  
Pleomorphic  adenoma  High  >  1.3  
Cellular  pleomorphic  adenoma  Iso  1—1.3  
Malignant  tumor:  low  grade  Iso  or  Hypo  1—1.3  
Malignant  tumor:  high  grade  Hypo  <  1  
Figure 10. Typical pleomorphic adenoma. Tissue structure in the sup
axial T2-weighted MRI: the lesion shows a pronounced hyperintense sig
intense contrast enhancement; c: mapping the apparent diffusion coefﬁc
with an ascending plateau.1231
his  sequence  alone  is  not  sufﬁcient  and  the  inter-
retation  should  incorporate  anatomical  features,  a  T2
equence  without  fat  saturation,  the  apparent  diffusion
oefﬁcient  ratio  (rADC)  and  the  lesion’s  T1  enhancement
urve.When  these  procedures  are  carried  out,  MRI  can  predict
he  histological  diagnosis  of  parotid  lesions  in  over  80%  of
ases.
 Perfusion  Others
Wash-out
>  30%
HighT1
Bilateral
Inferior  part
Man  >  50  y
Smoker
Ascending  plateau
Ascending  plateau
Wash-out
<  30%
Descending  plateau  Ill-deﬁned  margins
erﬁcial part of the left parotid gland, measuring 35 mm in size. a:
nal; b: axial T1-weighted MRI with gadolinium and fat saturation:
ient: rADC = 1.7; d: perfusion curve showing intense enhancement,
1232  S.  Espinoza  et  al.
Figure 11. Typical Warthin tumor. Tissue lesion a centimeter in size in the superﬁcial part of the right parotid gland. a: axial T1-weighted
MRI: the lesion contains small hyperintense spots without enhancement on the T1-weighted MRI; b: axial T2-weighted MRI: the lesion is
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•ypointense on the T2-weighted sequence; c: mapping of the appar
ntense contrast enhancement with a washout of over 30%.
erfusion imaging for UADT cancers
eneral details
ntil  now,  the  choice  of  ENT  oncology  treatments  has  been
ased  on  cohort  studies’  statistics.  The  recent  development
f  targeted  molecules  and  the  wide  range  of  treatments
hich  are  now  available  (chemotherapy,  radiotherapy  and
urgery)  make  it  essential  to  develop  tools  with  three  objec-
ives:
to  predict  whether  a  given  tumor  is  or  is  not  likely  to
respond  to  a  particular  type  of  non-surgical  treatment;
to  monitor  and  assess  response  during  treatment  in  order
to  adjust  the  treatment  as  soon  as  possible.  If  a  patient
fails  to  respond  adequately  or  does  not  respond  to  treat-
ment,  early  detection  of  the  treatment  failure  allows
the  care  to  be  changed.  This  may  involve  increasing  the
doses  of  chemotherapy  or  radiotherapy  or  adding  adju-
vant  chemotherapy.  It  may  also  involve  switching  sooner
to  surgery:  whilst  this  is  deﬁnitely  mutilating,  it  is  more
likely  to  achieve  satisfactory  local  control  and  a  lower
likelihood  of  complications  if  it  is  carried  out  on  non-
irradiated  tissue;
to detect  the  presence  of  residual  tumor  or  a  recurrence
after  conservative  treatment  as  early  as  possible,  in  order
to  organize  salvage  surgery  as  soon  as  possible.
•istribution coefﬁcient: rADC = 0.8; d: perfusion curve showing rapid
The  imaging  questions  which  arise  at  present  are  not
herefore  only  anatomical  ones  but  are  increasingly  func-
ional  (such  as  detection  of  viable  malignant  tissue  within
he  scarred  tissue).  The  main  purpose  of  this  is  to  increase
ocal  control  and  survival,  at  the  same  time  reducing
reatment-related  complications.  This  is  the  context  in
hich  perfusion  imaging  (CT  or  MRI)  is  being  developed  for
ADT  carcinomas,  and  in  which  this  new  technique  is  being
ssessed.
Perfusion  imaging  provides  non-invasive  access  to  the
icrocirculatory  properties  of  tumors.  The  perfusion
equence,  both  in  CT  and  MRI,  can  be  used  to  calculate
icrocirculatory  parameters  which  reﬂect  tumor  microvas-
ularization.  Both  CT  and  MRI  can  quantify  whether  the
emporal  resolution  and  acquisition  time  are  sufﬁcient,
ogether  with  tissue  blood  ﬂow  (TBF),  tissue  blood  volume
TBV),  mean  transit  time  (MTT)  and  surface  permeability
SP)  [10—16].
In  the  following  sections,  we  will  examine  how  tumor
maging  can  assist  in  the  following  by  assessing  the  micro-
irculatory  properties  of  tumors:
the  choice  of  initial  treatment  which  will  have  most
likelihood  of  success  in  a given  patient  (chemotherapy,
radiotherapy  or  surgery);
identifying  poor  responders  in  order  to  adjust  treatment
more  quickly;
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Figure 12. Cellular pleomorphic adenoma. Tissue lesion in the superﬁcial lobe of the right parotid gland, measuring 2 cm in size. a:
axial T2-weighted MRI: isointense lesion; b: axial T1-weighted MRI after gadolinium with fat saturation: intense contrast enhancement; c:
fusion
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•mapping of the apparent diffusion coefﬁcient: rADC = 1.09; d: per
plateau.
• quantitative  (objective)  monitoring  of  treatment
response;
• early  detection  of  recurrences  in  post-treatment  dam-
aged  tissue.
Technique and image processing
We  will  not  describe  the  CT  or  MRI  technique  here,  and  refer
the  reader  to  the  techniques  chapter.
We  would  simply  like  to  draw  the  reader’s  attention  to  a
few  speciﬁc  features  of  head  and  neck  imaging.
Choice  of  method,  CT  or  MRI
This  is  usually  dictated  by  the  site  of  the  primary  tumor,
the  patient’s  past  imaging  history  and  the  question  being
asked  by  the  clinician.  It  should  not  further  complicate
the  pre-treatment  assessment  of  patients  who  are  already
going  through  a  relatively  complex  staging  process  (initial
CT  and/or  MRI  imaging  depending  on  the  site,  PET  CT  inves-
tigating  for  a  second  primary,  biopsy).Lesions  of  the  cavum,  oropharynx,  oral  cavity  and  pos-
terior  pharyngeal  wall  should  preferably  be  investigated  by
MRI.  The  perfusion  MRI  sequence  is  only  an  additional  phase
of  the  investigation  (Fig.  15).
t
t curve showing intense contrast enhancement with an ascending
Lesions  of  the  hypopharynx  and  larynx  are  only  inves-
igated  by  CT  (unless  there  is  an  exception)  and  it  is
easonable  to  use  a  CT  perfusion  sequence  (Fig.  16).
The  initial  assessment  of  facial  tumors  usually  requires
oth  MRI  (to  demarcate  the  tumor,  identify  perineural  or
ven  intracranial  extensions,  and  to  distinguish  it  from
eighboring  inﬂammatory  reactions)  and  CT  (to  identify  cor-
ical  bone  structures  in  the  facial  bone  and  base  of  the
ranium  which  are  involved).  In  this  situation,  the  choice  of
ethod  is  guided  by  the  radiologist’s  personal  experience
nd  the  patient’s  past  radiological  history.
peciﬁc  features  of  the  ENT  perfusion  sequence
n  CT  [17]:
80 kV  acquisition  with  dose  modulation  (angular  and  z)
between  20  and  100  mA,  2.5  mm  sections,  FOV  =  20  cm,
soft  ﬁlter  reconstruction;
injection:  40  mL  at  5  mL/s  by  pulsed  bolus,  concentration
320  mgI/mL;
acquisition:  5  s after  the  start  of  the  injection,  minimum
time  60  s,  temporal  resolution:  1/s;
gentle  breathing  without  swallowing.On  MRI  and  CT,  for  UADT  carcinomas,  the  issue  of  den-
al  artifacts  arises:  the  patient  should  be  tilted  to  minimize
hese.
1234  S.  Espinoza  et  al.
Figure 13. Intermediary-grade malignant tumor. Tissue lesion in the superﬁcial part of the right parotid gland. a: axial T2-weighted MRI:
hypointense; b: axial T1-weighted MRI after gadolinium with fat saturat
coefﬁcient: rADC = 1.1; d: perfusion curve showing early contrast enhanc
Boxed  text  2  Acquisition  parameters  for  CT
perfusion  sequence.
Injection:  40  mL  via  a  power  injector  at  a  rate  of
4  mL/s,  followed  by  injection  of  40  mL  of  normal  saline
80  kV/80  mAs
Section  thickness:  2.5  mm
Temporal  resolution:  1/s  during  the  ﬁrst  min
Acquisition  duration:  4  min  30  s
Matrix:  192  ×  192
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QFOV:  28  cm
Choice  of  arterial  input  functional  ROI:  there  is  no
onsensus  on  this.  It  would  seem  reasonable  to  position  this
n  the  ipsilateral  external  carotid  artery,  as  close  as  possible
o  the  lesion  (Boxed  text  2).
nterpretation of microcirculation indices
re-treatment
he  aim  here  is  to  predict  the  likelihood  of  local  control  and
omplete  response  to  conservative  treatment.  It  has  been
emonstrated  that:
TBF  and  TBV  predict  the  level  of  chemosensitivity.  The
higher  these  indices  are,  the  more  chemosensitive  the
a
t
Iion: moderate enhancement; c: mapping of the apparent diffusion
ement with washout of under 30%.
lesion  is  [15,18].  In  particular,  a  high  pre-treatment  TBV
is  a  marker  of  good  response  to  non-surgical  treatment,
with  a  greater  likelihood  of  complete  response  with
radiochemotherapy  [15];
TBF,  calculated  from  the  perfusion  CT,  is  an  independent
marker  of  failure  of  radiotherapy:  hypoperfused  tumors
respond  less  well  to  radiotherapy,  as  they  are  poorly  oxy-
genated  [19];
SP  predicts  the  likelihood  of  local  control  after  non-
surgical  treatment  [18].
It  also  appears  that:
the  MTT  correlates  with  the  level  of  malignancy  [13,14].
An  MTT  of  less  than  3.5  s  is  evidence  of  a  malignant  lesion,
whereas  an  MTT  more  than  5.5  s  signiﬁes  a  benign  lesion.
This  reduction  is  due  to  neoangiogenesis,  with  raised  per-
fusion  pressure  and  raised  capillary  permeability;
TBF  and  TBV  correlate  with  microvascular  density  [16];
results  for  SP  are  discordant,  and  additional  studies  are
required  to  establish  whether  SP  is  or  is  not  a  marker  of
neoangiogenesis  [13,16].
uantitative  assessment  of  response  to  treatments
nd monitoring  response  to  non-surgical
reatments
t  has  been  shown  that:
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Figure 14. High-grade malignant tumor. Tissue structure in the superﬁcial lobe of the left parotid gland, measuring 3 cm in size. a: axial
T2-weighted MRI: isointense; b: axial T1-weighted MRI after gadolinium with fat saturation: moderate contrast enhancement; c: diffusion
mapping: rADC = 0.5; d: perfusion curve showing a descending plateau with washout of under 30%.
Figure 15. CT versus MRI of the cavum. a: CT: sagittal reconstruction centered on the cavum; b: MRI: sagittal T1-weighted sequence with
gadolinium and fat saturation centered on the cavum. Note that the enhancement resolution is better on MRI.
1236  S.  Espinoza  et  al.
Figure 16. CT versus MRI of the larynx. a: MRI: coronal T1-weighted sequence after gadolinium with fat saturation centered on the
larynx. Right supra-glottal structure with peripheral enhancement; b: CT: coronal reconstruction of the larynx. Note that the differentiation
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Petween the lesion (black asterisk) and the thyroid cartilage (black
avity (white asterisk) is clear on CT.
the  change  in  TBV  is  a  good  indicator  of  response:  a  20%
fall  correlates  with  an  endoscopic  response  of  over  50%
[20];
a successive  fall  in  TBV  and  TBF  [21]  is  an  objective,  quan-
titative  method  to  detect  tumors  which  have  responded
to  neo-adjuvant  chemotherapy;
a  repeated  persistent  fall  in  TBV  during  treatment  is  a
predictor  of  response  [21];
a progressive  rise  in  TBV  is  characteristic  of  non-
responders  to  radiochemotherapy  [21].
etection  of  recurrences
he  best  detection  method  for  detecting  recurrences
ppears  to  be  PET  CT  with  MRI  [22],  although  these  pre-
iminary  ﬁndings  need  to  be  conﬁrmed  in  studies  on  larger
umbers.
A  new  rise  in  TBF  after  radiochemotherapy  treatment
ould  appear  to  help  to  detect  relapse  within  non-speciﬁc
ost-treatment  tissue  changes  [23,24].
The  main  established  values  for  microcirculation  param-
ters  are  summarized  in  Table  2.
An  example  of  the  use  of  MRI  is  shown  in  Fig.  17.
haracterization  of  lymph  nodes  under  a
entimeter in  size  [22]
here  is  still  a  major  problem  with  characterizing  lymph
odes  under  a  centimeter  in  size.  Combining  PET  CT  with
iffusion-weighted  MRI  currently  appears  to  be  the  best
ption  to  detect  small  invaded  lymph  nodes  [22].  Perfusion
v
s
s
ow) is better, and visualization of the fat in the hyo-thyro-epiglottic
maging  does  not  perform  well  in  this  situation  because  of
he  small  number  of  sections  which  can  be  investigated  and
he  need  to  decide  on  the  lymph  nodes  to  be  examined  in
dvance.
ummary
T  or  MRI  perfusion  imaging  can  identify  the  microcir-
ulatory  features  of  tumors.  Initial  work  suggests  that
his  method  should  help  to  predict  response  to  non-
urgical  treatment  in  order  to  optimally  adjust  it,  monitor
esponse  to  the  treatment  quantitatively  and  detect
elapses  after  conservative  treatment  early  [25].  Validat-
ng  this  technique  therefore  appears  to  be  the  ﬁrst  stage
owards  dose  modulation  for  each  investigation,  allow-
ng  individually  customized  treatment.  Technical  difﬁculties
emain,  however,  and  are  described  in  the  most  recent
ublications  which  have  returned  to  the  physical  bases
nd  principles  of  calculating  microcirculatory  parameters
26,27].
onclusion
erfusion  imaging  has  become  a  routine  MRI  tool  for  sali-
ary  gland  tumors.  A  good  investigation  should  include  a  T2
equence  combined  with  diffusion-weighted  and  perfusion
equence.  Under  these  conditions,  MRI  can  predict  the  type
f  lesion  in  over  80%  of  cases.
Perfusion  in  ENT  imaging  1237
Figure 17. Monitoring a left submaxillary tumor. First line: before treatment: a: perfusion curve before treatment showing a descending
plateau suggesting a malignant tumor; b: mapping of the positive enhancement integral before treatment: note the peripheral hypervascular
crown shown in yellow and red, indicating extensive vascularization within the lesion; c: ADC mapping before treatment: low rADC of 1.1.
Second line: after treatment: d: perfusion curve after treatment showing an ascending plateau; e: mapping of the positive enhancement
integral after treatment: note the disappearance of the peripheral hypervascular crown in yellow and red, indicating a reduction in the
vascularization within the lesion; f: ADC mapping after treatment: high rADC of 1.45.
Table  2  Literature  data.
MTT  TBF  TBV  PS
Before  treatment  Chemosensitive  when
high  value
Chemosensitive  when
high  value
Predictive  local
control
During  treatment  Decrease  with  response  Decrease  with  response
Increase  with  no
response
Other  Correlated  to
malignancy
Correlated  to
malignancy  and
microvascular  density
Correlated  to
malignancy  and
microvascular  density
Correlated  to
malignancy
1 S.  Espinoza  et  al.
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5. What  should  you  tell  the  patient  and  what  treatment
should  be  considered?
Answers
1.  MRI  shows  a  15  mm  tissue  lesion  within  the  right  parotid
gland,  located  in  the  superﬁcial  part  of  the  gland.  There  is
a  slight  unenhanced  hyperintensity  within  the  lesion  on  the
T1-weighted  sequence.  The  T2-weighted  signal  is  heteroge-
neous,  with  isointense  areas  and  pronounced  hypointense
areas  on  a T2-weighted  sequence.  The  lesion  is  isointense
compared  to  the  rest  of  the  glandular  parenchyma  on  the
late  phase  after  enhancement.  Diffusion  mapping  shows  an
ADC  of  0.6  and  the  perfusion  curve  shows  an  early  peak  with
a  30%  washout.
2.  The  question  to  ask  the  patient  is:  ‘‘Have  you  done
a  needle  aspiration  of  the  lesion?’’  A  needle  aspiration
before  the  MRI  could  cause  bleeding  inside  the  lesion.  The
T1-weighted  hyperintensity  is  not  signiﬁcant  if  a  needle  aspi-
ration  was  taken  before  the  MRI.  In  this  case,  the  MRI  would
need  to  be  repeated  a  month  later.  In  this  case,  no  needle
aspiration  had  been  performed  before  the  MRI.
3.  The  diagnosis  is  that  of  a  typical  Warthin  tumor
because  of  an  unenhanced  T1-weighted  hyperintensity  and
30%  washout.  These  lesions  often  have  an  rADC  of  between
0.6  and  1:  this  is  not  therefore  incompatible  with  the  diag-
nosis.  In  addition,  the  lesions  show  intense  uptake  on  PET
CT.  This  is  an  increasingly  common  diagnosis  because  of  the
increased  use  of  this  type  of  investigation  in  all  oncology
assessments,  particularly  in  ENT.
4.  The  diagnosis  must  be  conﬁrmed  by  a  needle  aspira-
tion,  which  did  conﬁrm  this  diagnosis.
5.  This  is  a  benign  tumor  with  no  risk  of  malignant  degen-
eration  and  surgery  is  not  indicated.  MRI  monitoring  alone
may  be  sufﬁcient,  although  is  not  really  essential.  The  lesion
may  change  in  size  and  signal  as  a  result  of  episodes  of
inﬂammation  or  bleeding  within  the  lesion.238  
Perfusion  imaging  is  a  promising  tool  for  other  head  and
eck  tumors,  particularly  UADT  carcinomas,  which  should
elp  us  to  meet  clinicians’  expectations  in  the  future.  Perfu-
ion  imaging  is  always  the  ﬁrst  step  towards  dose  modulation
nd  allows  treatment  to  be  adapted  to  the  patient.
TAKE-HOME  MESSAGES
Salivary  glands:
• a T1-weighted  perfusion  sequence  is  essential  in
characterizing  salivary  gland  tumors;
• temporal  resolution  must  involve  one  set  of  images
every  3  to  4  s;
• the  sequence  should  last  4  to  5  min;
• the  choice  of  ROI  is  very  important.  This  should  be
positioned:
◦ outside  of  cystic  and  hemorrhagic  areas,
◦ outside  of  T1  hyperintense  areas,
◦ inside  T1  and  T2  hypointense  areas;
• the  curve  can  only  be  interpreted  in  conjunction  with
conventional  imaging:
◦ a  washout  of  over  30%  is  highly  suggestive  of  a
Warthin  tumor,
◦ an  ascending  plateau  with  no  washout  suggests  a
pleomorphic  adenoma,
◦ a  descending  plateau  suggests  a  malignant  tumor;
• a  full  investigation  protocol  should  include  T1  and  T2
sequences  without  fat  saturation,  T1  diffusion  and
perfusion  sequences  and  a  fat  saturation  gadolinium
enhanced  T1-weighted  sequence;
• interpretation  should  take  all  of  the  anatomical,
signal  abnormality  and  functional  ﬁndings  into
account.
UADT  carcinomas:
• the  perfusion  sequence  appears  to  be  useful  for
selecting  and  monitoring  treatments;
• the  perfusion  sequence  can  be  performed  by  CT  or
T1-weighted  MRI;
• the  spatial  resolution  should  be:
◦ one  set  of  images  per  second  by  CT,
◦ one  set  of  images  every  3  to  4  s  by  MRI;
• TBV  and  TBF  are  the  best  predictive  indicators  of
response  to  conservative  treatment  and  can  be  used
to  monitor  lesions  which  are  currently  being  treated.
linical case report
his  79-year-old  patient  is  being  followed  up  for  bladder
ancer.  PET  CT  shows  right  parotid  uptake  with  an  SUV  of
.3  (Fig.  18).  This  is  his  MRI  (Fig.  19).
uestions.  Describe  the  abnormalities  on  MRI.
2.  What  question  should  the  patient  be  asked?
3.  What  is  your  diagnosis?
4.  How  do  you  conﬁrm  it? Figure 18. PET CT shows right parotid uptake with an SUV = 5.3.
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 MRI
 T1-wFigure 19. MRI: a: axial T1-weighted MRI; b: axial T2-weighted
T1-weighted MRI after enhancement with fat saturation; f: coronal
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